Lucid Diagnostics Inc. reported the first quarter ended March 31, 2026 results: revenue $1.3 million, net income $23.6 million, EPS $(0.17) per common share.
“(EX-99.1) --- Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May”
Material Agreements
Lucid Diagnostics Inc. entered into Underwriting Agreement with Canaccord Genuity LLC and BTIG, LLC, as representatives of the underwriters (effective 2026-04-23).
“On April 23, 2026, Lucid Diagnostics Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Canaccord Genuity LLC and BTIG, LLC, as representatives (the “ Representatives ”) of the underwriters named therein (the “ Underwriters ”), for an underwritten offering to the public of shares of the Company’s common stock”
Earnings Releases
Lucid Diagnostics Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.5 million, net income approximately $16.3 million or $(0.12) per common share, EPS $(0.12) per common share.
“--- Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world”
Auditor Changes
Lucid Diagnostics Inc. engaged CBIZ CPAs P.C. as its auditor.
“CBIZ CPAs was engaged as the Company’s independent registered public accounting firm on the same date.”
Auditor Changes
Marcum LLP resigned as auditor of Lucid Diagnostics Inc..
“Marcum resigned as the independent registered public accounting firm of Lucid Diagnostics Inc.”
Earnings Releases
Lucid Diagnostics Inc. reported the three months ended March 31, 2024 results: revenue $1.0 million, net income $18.1 million or $(0.40) per common share, EPS $(0.40) per common share.
“regional plans in biomarker legislation states and pilots with national plans. Financial Results ● For the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $11.8 million, which included stock-based compensation expenses of $0.9 million. GAAP net loss attributable to common stockholders was”
Governance Changes
Lucid Diagnostics Inc.: Amended and Restated Certificate of Incorporation authorizes up to 20 million shares of preferred stock and designates Series B-1 Preferred Stock.
“Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth under Item 3.02 is incorporated herein by reference. The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Certificate of Designation designates up to 11,634 of the shares of preferred stock as Series B-1 Preferred Stock.”
Dennis Matheis was appointed as Class A Director at Lucid Diagnostics Inc..
“Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.”
“The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Series B Certificate of Designation designates up to 56,000 of the shares of preferred stock as Series B Preferred Stock and the Series A-1 Certificate of Amendment increases the number of shares designated as Series A-1 Preferred Stock by 5,670 shares.”
Listing & Compliance Notices
Lucid Diagnostics Inc. received a nasdaq deficiency notice notice regarding market value.
“received a notice from the Nasdaq Listing Qualifications Department stating that the Company was no longer in compliance with the Equity standard for continued listing on the Nasdaq Global Market (and that the Company did not meet the alternative standards for Market Value or Total Assets/Total Revenue). Upon the transfer of the listing of the Company’s common stock to the Nasdaq Capital Market, this deficiency will be resolved because the Company presently meets the continued listing standards for the Nasdaq Capital Market.”
Listing & Compliance Notices
Lucid Diagnostics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“continued listing under the Equity Standard. Because the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 reported stockholders’ equity of $2,556,000 (and because the Company does not meet the alternative standards for Market Value or Total Assets/Total Revenue), the Company has fallen out of compliance with the continued”
Earnings Releases
Lucid Diagnostics Inc. reported the three and nine months ended September 30, 2023 results: revenue $0.8 million, net income $14.2 million, or $(0.34) per common share, EPS $(0.34) per common share.
“and platform expected to significantly lower per-sample sequencing costs. Financial Results ● For the three months ended September 30, 2023, EsoGuard related revenues were $0.8 million. Operating expenses were approximately $11.9 million, including stock-based compensation expenses of $1.3 million. GAAP net loss was approximately $14.2 million, or $(0.34) per”
Shaun M. O'Neil was appointed as President at Lucid Diagnostics Inc..
“Effective on November 6, 2023, the board of directors (the “ Board ”) of Lucid Diagnostics Inc. (the “ Company ”) appointed Shaun M. O’Neil as the President of the Company.”
Governance Changes
Lucid Diagnostics Inc.: Amended and Restated Certificate of Incorporation authorizes up to 20,000,000 shares of preferred stock and designates up to 5,000 shares as Series A-1 Preferred Stock.
“The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Certificate of Designation designates up to 5,000 of the shares of preferred stock as Series A-1 Preferred Stock.”
Governance Changes
Lucid Diagnostics Inc.: Amended certificate of incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares (effective 2023-06-21).
“b. A proposal to amend the Certificate of Incorporation to increase the total number of shares of common stock the Company is authorized to issue by 100,000,000 shares, from 100,000,000 shares to 200,000,000 shares. The amendment was approved”
Governance Changes
Lucid Diagnostics Inc.: Amended certificate of incorporation to incorporate new Delaware law provisions regarding officer exculpation (effective 2023-06-21).
“a. A proposal to amend the Company’s certificate of incorporation, as amended (the “ Certificate of Incorporation ”), to incorporate new Delaware law provisions regarding officer exculpation. The amendment was approved”
Shareholder Votes
Lucid Diagnostics Inc. shareholders approved Ratify appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.
“A proposal to ratify the appointment of Marcum LLP as the Company’s independent registered certified public accounting firm for the year ending December 31, 2023. The ratification of the appointment of Marcum LLP was approved, as follows: For Against Abstain Broker Non-Votes 38,255,914 18,190 88,653 —”
Shareholder Votes
Lucid Diagnostics Inc. shareholders approved Approve issuance of shares under Series A Convertible Preferred Stock sold in March 2023 at the 2023-06-21 meeting.
“A proposal to approve, for the purposes of Listing Rule 5635 of Nasdaq, the issuance of shares of the Company’s common stock under the Series A Convertible Preferred Stock (the “ Series A Preferred Stock ”) sold by the Company in a private offering commenced in March 2023. The issuance was approved, as follows: For Against Abstain Broker Non-Votes 34,176,748 144,141 39,501 4,002,367”
Shareholder Votes
Lucid Diagnostics Inc. shareholders approved Approve issuance of shares under Senior Secured Convertible Note sold in March 2023 at the 2023-06-21 meeting.
“A proposal to approve, for the purposes of Listing Rule 5635 of The Nasdaq Stock Market LLC (“ Nasdaq ”), the issuance of shares of the Company’s common stock under the Senior Secured Convertible Note (the “ March 2023 Note ”) sold by the Company in a private offering in March 2023. The issuance was approved, as follows: For Against Abstain Broker Non-Votes 34,220,820 100,068 39,502 4,002,367”
Shareholder Votes
Lucid Diagnostics Inc. shareholders approved Amend certificate of incorporation to increase total number of authorized shares of common stock from 100,000,000 to 200,000,000 at the 2023-06-21 meeting.
“A proposal to amend the Certificate of Incorporation to increase the total number of shares of common stock the Company is authorized to issue by 100,000,000 shares, from 100,000,000 shares to 200,000,000 shares. The amendment was approved, as follows: For Against Abstain Broker Non-Votes 37,115,102 1,125,504 122,151 —”
Shareholder Votes
Lucid Diagnostics Inc. shareholders approved Amend certificate of incorporation to incorporate new Delaware law provisions regarding officer exculpation at the 2023-06-21 meeting.
“A proposal to amend the Company’s certificate of incorporation, as amended (the “ Certificate of Incorporation ”), to incorporate new Delaware law provisions regarding officer exculpation. The amendment was approved, as follows: For Against Abstain Broker Non-Votes 33,334,308 985,133 40,949 4,002,367”
Shareholder Votes
Lucid Diagnostics Inc. shareholders approved Election of two Class B directors at the 2023-06-21 meeting.
“The board nominated Mr. Sparks and Dr. Cox for re-election as Class B directors. Each of the board’s nominees for director was elected, as follows: Name For Authority Withheld Broker Non-Votes Ronald M. Sparks 34,163,239 197,151 4,002,367 James L. Cox, M.D. 34,154,419 205,971 4,002,367”
Governance Changes
Lucid Diagnostics Inc.: Amended and restated certificate of incorporation authorizing 20,000,000 shares of preferred stock and designating up to 20,000 shares as Series A Preferred Stock.
“The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Certificate of Designation designates up to 20,000 of the shares of preferred stock as Series A Preferred Stock.”
Material Agreements
Lucid Diagnostics Inc. terminated Management Services Agreement with ResearchDx, Inc. valued at Remaining earnout and management fees reduced to $725,000 from approx. $3,450,000, net savings of ap (effective 2023-02-10).
“On February 14, 2023, Lucid Diagnostics Inc. (the “ Company ” or “ Lucid Diagnostics ”) and LucidDx Labs Inc. (“ LucidDx Labs ”), a wholly owned subsidiary of the Company, entered into an agreement (the “ Termination Agreement ”) with ResearchDx, Inc. (“ RDx ”), pursuant to which the parties mutually agreed to terminate the Management Services Agreement, dated as of February 25, 2022, by and between LucidDx Labs and RDx (the “ MSA ”), without cause. The termination was effective as of February 10, 2023.”
Earnings Releases
Lucid Diagnostics Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $14.3 million, EPS $(0.39) per common share.
“For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $14.4 million, including stock-based compensation expenses of $3.6 million. GAAP net loss attributable to common stockholders was approximately $14.3 million, or $(0.39) per common share.”
Aster Angagaw resigned as director at Lucid Diagnostics Inc..
“Ms. White replaces Aster Angagaw, who resigned as a director effective on July 30, 2022.”
Debra J. White was appointed as Class C director at Lucid Diagnostics Inc..
“appointed Debra J. White as a Class C director of the Company.”
David F. Wurtman resigned as Chief Medical Officer at Lucid Diagnostics Inc..
“On March 1, 2022, David F. Wurtman, M.D. resigned from his position as Chief Medical Officer of the Company, effective as of March 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.